NIRAMAI Health Analytix

What NIRAMAI Health Analytix does

NIRAMAI Health Analytix is a Bangalore-based deep-tech healthcare company founded in 2016 by Dr. Geetha Manjunath and Nidhi Mathur, focused on AI-powered breast cancer screening. The company's core product, Thermalytix, is a radiation-free, non-contact medical device that combines high-resolution infrared thermal imaging with proprietary machine learning and deep learning algorithms to analyze 400,000 temperature points per image and detect breast abnormalities through vascular biomarker analysis and automated risk stratification (B-Score). The technology is backed by 39 granted patents and 55+ clinically reviewed publications, with regulatory clearances including US FDA 510(k) for the SMILE-100 System, CE Mark for Europe, CDSCO approval in India, and ISO 13485 / MDSAP certifications.

The product portfolio spans three tiers: the flagship Thermalytix AI analysis engine for hospitals and diagnostic centers; the SMILE-100 System (US FDA-cleared) as a regulated thermal imaging device; and Mythri Thermalytix, a mobile, low-cost device with offline capability for primary healthcare and rural screening. Service-layer offerings include home breast screening, corporate wellness camps, and community outreach programs. The company generates revenue through a hybrid model combining hardware sales and rentals, software licensing, per-scan transaction fees (approximately $15 standard, $1.50-$3 subsidized), and direct-to-consumer home screening services.

NIRAMAI serves a diverse customer base across 22+ countries including 150+ installations at enterprise hospital chains (Apollo Clinics, HCG, Narayana Health, Rainbow Hospitals, Medanta), diagnostic networks (Dr Lal Path Labs, Medall, ISHA), government health programs (Punjab Government, BBMP), NGOs (Karnataka Cancer Society, Action Pink), and individual consumers via home screening partnerships. The company has cumulatively screened 300,000-500,000+ women and operates with 51-100 employees, supported by approximately $7M in total disclosed funding led by pi Ventures, with recent distribution scaled through a partnership with Molbio Diagnostics.

Name

NIRAMAI Health Analytix

Legal name

Niramai Health Analytix Private Limited

Website

https://niramai.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

NIRAMAI Health Analytix develops Thermalytix, an AI-powered thermal imaging platform for radiation-free, non-contact breast cancer screening serving hospitals, diagnostic chains, government health programs, NGOs, and individual consumers across 22+ countries with FDA-cleared, CE-marked medical device products.

Ownership category

akta.pro rank

Product category

AI Breast Cancer Screening

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical and Diagnostic Laboratories (62151), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)

akta.pro primary industry

Mammography & Breast Imaging Systems (HLAHABAF)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Breast Imaging Centers (Mammography/Tomosynthesis) (HLAFAKAD), Women’s Imaging & Breast Health Centers (HLAFAJAJ), Breast Oncology (HLAKAFAJ)

Keywords

• AI medical imaging
• Breast cancer screening
• Thermal imaging diagnostics
• Radiation-free screening
• Healthcare AI software

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Screening Test Fees: Direct revenue from breast cancer screening tests performed at hospitals, diagnostic centers, and screening camps. Per-test pricing for individual consumers and negotiated rates for corporate/government programs.
2. Equipment Sales and Rental: Sale and rental of Thermalytix hardware and Mythri devices to healthcare providers, hospitals, and diagnostic chains. Equipment available for purchase or monthly/daily rental basis for corporate and NGO screening programs.
3. Software Licensing: Thermalytix software licensing to hospitals and diagnostic centers for AI-powered breast cancer screening analysis. Cloud-hosted analytics solution with radiologist-certified reporting.
4. Home Screening Service: Direct-to-consumer home screening service with trained female technicians visiting homes for private breast health screening. Booking through website with service fees per screening.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels6 records

Core offering

NIRAMAI Health Analytix develops and commercializes Thermalytix, an AI-powered breast cancer screening platform that uses thermal imaging combined with proprietary machine learning and deep learning algorithms to analyze 400,000 temperature points per image for detecting early-stage breast abnormalities. The offering spans the Thermalytix AI software engine, the US FDA-cleared SMILE-100 thermal imaging medical device, and the portable Mythri Thermalytix device, deployed across hospitals, diagnostic centers, community screening programs, government health missions, and direct-to-consumer home screening services.

Product overview

NIRAMAI Health Analytix offers a portfolio of AI-powered breast cancer screening products centered on its core Thermalytix technology — a radiation-free, non-contact thermal imaging solution enhanced with machine learning and deep learning algorithms. The product line spans three tiers: the flagship Thermalytix AI analysis engine (CE Mark, CDSCO approved) used in hospitals and diagnostic centers; the SMILE-100 System (US FDA cleared) as a regulated thermal imaging device for adjunct breast screening; and Mythri (India-only) as a mobile, low-cost triaging tool for rural and primary-care settings. Service-layer offerings include at-home screening, community outreach programs with NGO/government partnerships, and corporate wellness camps. All products share the same AI core — analyzing thermal images for quantitative breast health scoring — while differing in regulatory clearance scope, portability, and target deployment environment.

Differentiator

Problem solved

Functional benefit

Brands

• Thermalytix: Novel AI-based medical device for early breast cancer screening using thermal imaging and machine learning algorithms. The core patented technology of Niramai, providing radiation-free, non-contact, portable breast cancer detection for women of all ages and breast densities.
• SMILE-100 System
• Mythri Thermalytix

Products and services

• Thermalytix AI-powered breast cancer screening solution that uses thermal imaging combined with machine learning and deep learning algorithms to analyze 400,000 temperature points on the chest for detecting early-stage breast abnormalities. Radiation-free, non-contact, portable, and effective for women of all ages and breast densities. Generates a quantitative breast health score (B-Score) and risk stratification report reviewed by radiologists. Deployed at hospitals, diagnostic centers, and community screening programs.
• Niramai SMILE-100 System (BreastHealth-100) US FDA 510(k) cleared thermal imaging medical device (also called BreastHealth-100) for adjunct breast health screening. Helps healthcare personnel review, measure, and analyze thermally significant indications in the breast region. Includes AI-based image quality check to reduce errors in thermal capture and a subset of Thermalytix functionality with vascularity analysis and AI-based scoring. Cleared for use in hospital, acute care, outpatient surgery, and healthcare practitioner facilities.
• Mythri Thermalytix Mobile-based, low-cost breast health screening device powered by Thermalytix AI. Designed for triaging and risk assessment in primary healthcare centers, rural camps, and resource-constrained settings. Features offline-mode operation, compact portable design, and rapid results delivery with minimal technician training required. Available only in India.
• Home Breast Screening Service At-home breast cancer screening service where a trained female technician visits the customer's home to conduct Thermalytix screening in a private, contactless process. Available in select cities in partnership with Healthians, Apollo, MiyaraWomen, and ProactiveForHer, and bookable directly through the company website.
• Community Screening and Outreach Program (with Easy Launch Kits) Portable screening setup for RWAs, NGOs, corporate CSR programs, and government health initiatives. Includes Easy Launch Kits for NGOs enabling screening at Rs 1,000/day, mobile health unit deployments, and capacity building for community health workers. Integrates with government programs via GeM procurement.
• Corporate Wellness Screening On-site breast cancer screening and education camps for corporate employees as part of workplace wellness initiatives, offering accessible and privacy-aware screening within corporate premises. Targeted at HR teams and CSR program heads providing breast cancer screening benefits to female employees.

Quantifiable outcome

• 50x greater thermal sensitivity (0.02°C) compared to conventional thermography (1°C)
• +6 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

15 partnerships are on record, tiered core and minor.

• Action Pink (Germany)coreStrategic or Co-development Partner · 17 April 2024Global partnership with German NGO Action Pink, led by CEO Corinna Saric, for breast cancer awareness and early detection advocacy. Combines NIRAMAI's AI technology with Action Pink's advocacy efforts to enhance early detection rates and improve outcomes globally.
• Molbio DiagnosticscoreChannel Partner/ Reseller/ Distributor · 12 April 2024Partnership for global promotion and distribution of Thermalytix in both public and private healthcare markets. Molbio Diagnostics leverages its extensive distribution network to expand access to AI-powered breast cancer screening worldwide.
• Apollo ClinicscoreChannel Partner/ Reseller/ DistributorMulti-city deployment of Thermalytix screening across Apollo's clinic network in India, making breast cancer screening accessible to patients visiting Apollo facilities.
• HCG Cancer HospitalscoreChannel Partner/ Reseller/ DistributorAI-powered breast cancer screening integration at HCG's cancer treatment facilities, combining NIRAMAI's technology with HCG's oncology expertise.
• Narayana HealthcoreChannel Partner/ Reseller/ DistributorScreening services at Narayana Health clinics in Bangalore and Electronic City, providing accessible breast health screening options.
• Rainbow HospitalsminorChannel Partner/ Reseller/ DistributorPartner hospital for breast cancer screening services and outreach programs focused on women's health.
• MedantaminorChannel Partner/ Reseller/ DistributorBreast health screening integration at Medanta's multi-specialty healthcare facilities.
• Medall DiagnosticsminorChannel Partner/ Reseller/ DistributorDistribution partnership for AI-powered breast cancer screening tests across Medall's diagnostic network.
• HealthiansminorChannel Partner/ Reseller/ DistributorHome screening service partnership, with Healthians providing trained professionals for at-home breast cancer screening.
• ISHA DiagnosticsminorImplementation/ SI/ Consulting PartnerCME seminar partnership and launch of NIRAMAI Thermal Mammography at ISHA Diagnostics, including joint continued medical education programs for gynecologists.
• Karnataka Cancer SocietycoreStrategic or Co-development PartnerLong-term partnership conducting over 25 screening camps and screening 750+ women. Karnataka Cancer Society leverages portable NIRAMAI technology for rural outreach and community screening programs.
• Punjab Government Health DepartmentcoreStrategic or Co-development PartnerAI-digital breast cancer screening project screening 15,069 women at population level. Government partnership for large-scale public health screening implementation.
• ACT GrantminorStrategic or Co-development PartnerACT Grant partnership providing 5,000+ screenings in Andhra Pradesh as part of health initiative for underserved populations.
• Mission AnandiminorStrategic or Co-development PartnerJoint initiative with Osmanabad District Administration and Transform Rural India for 25,000 women to receive AI-based screening in rural Maharashtra.
• FICCI Smart AAMsminorStrategic or Co-development PartnerPartnership under FICCI Smart AAMs program screening 6,000+ women with AI-powered Thermalytix in primary care centers.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Emerging players

• Densitas: Canadian AI breast density and image quality vendor. Comparable in providing AI-driven adjunct analysis on mammography and similar risk-stratification goals to NIRAMAI's B-Score.

Broad incumbents

• Hologic: US-listed leader in mammography (3Dimensions, Genius AI) with dominant installed base in breast imaging. Comparable to NIRAMAI in target use case (breast cancer screening) but with vastly larger capital base, deeper hospital channel, and reimbursement infrastructure that NIRAMAI must compete against.
• Siemens Healthineers: Global mammography and AI imaging incumbent with large installed base and AI-augmented workflows. Comparable as an established competitor in breast imaging that NIRAMAI's portable thermal solution must coexist with in hospital procurement cycles.
• GE HealthCare: Global mammography (Pristina) and AI imaging vendor with broad hospital contracts. Comparable in target clinical use case (breast cancer screening) and as a primary competitor for hospital capital budgets that NIRAMAI must displace or co-sell alongside.

Direct peers

• iCAD: AI breast imaging specialist (ProFound AI for mammography, PowerLook Density). Directly comparable as an AI-augmented breast cancer detection vendor pursuing adjunct positioning similar to NIRAMAI's FDA-cleared SMILE-100, with established US commercial footprint.
• Volpara Health Technologies: AI breast density and risk assessment platform (Volpara Density, Volpara Risk). Directly comparable in automating breast imaging interpretation and risk stratification, with both SaaS positioning and clinical evidence-based go-to-market similar to NIRAMAI's B-Score approach.
• Therapixel: French AI mammography vendor with FDA-cleared MammoScreen 2.x for adjunct screening. Closely comparable in being a dedicated AI mammography/adjunct vendor pursuing the same clinical positioning as NIRAMAI's SMILE-100.
• Lunit: Korean publicly-listed AI imaging company (Lunit INSIGHT MMG for mammography). Comparable as a pure-play AI breast imaging vendor with FDA clearances, global commercial presence, and academic publication record similar to NIRAMAI.
• DeepHealth (RadNet subsidiary): RadNet-owned AI breast imaging vendor (Saige-Dx FDA-cleared product). Directly comparable as an AI-mammography vendor pursuing adjunct and triage use cases similar to NIRAMAI, with deeper US distribution through RadNet.

Regional players

• Tricog Health: India-based AI diagnostic company focused on cardiac ECG triage. Comparable as an India-headquartered AI health-tech vendor with similar go-to-market pattern (partnerships with Indian hospital networks, public health deployments) to NIRAMAI, though in a different clinical vertical.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@niramai
• LinkedInlinkedin.com/company/niramai-health-analytix
• Instagraminstagram.com/niramai_health_analytix
• Xx.com/niramaianalytix
• Facebookfacebook.com/niramaianalytix

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NIRAMAI Health Analytix